Abstract: A chewing gum composition with high pH-release includes an insoluble gum base matrix and a soluble bulk portion, wherein the gum base matrix and the bulk portion is mixed and extruded to form a final chewing gum core, and wherein the gum base matrix is buffered before mixing with the bulk portion. Furthermore, a method of producing a chewing gum core, wherein a gum base matrix and a bulk portion is mixed and extruded to form a final chewing gum core, and wherein the gum base matrix is buffered before mixing with the bulk portion, and the gum base matrix includes a first amount of buffer from 2 to 20 percent by weight of the gum base matrix before mixing with the bulk portion.

Abstract: The present invention relates to a method of preparing a composite biomaterial, essentially consisting of collagen in combination with granules of hydroxyapatite/?-tricalcium phosphate (HA/?-TCP), to be used in maxillofacial surgery, dentistry, aesthetic surgery and particularly in orthopedic surgery; the invention also relates to the biomaterial obtained by means of this method.

Abstract: A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol and a sorbitan ester. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti-bacterial activity and reducing the expression of pro-inflammatory mediators. If isopropyl is selected, then the sorbitan ester is at least one of polyoxyethylene 20 sorbitan monooleate, and a proviso that if isobutyl magnolol is selected, then the sorbitan ester is poloxyethylene 20 sorbitan monooleate.

Abstract: A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain, such as hyperalgesia and/or allodynia, for at least one week, and preferably longer at the site, and preferably the region (e.g. entire limb), where the nerve block was applied. The site 1 sodium channel blocker is preferably saxitoxin (STX), preferably in combination with a corticosteroid, preferably dexamethasone. In a preferred embodiment, liposomes are included in the formulation as a controlled release system, producing prolonged duration of block without systemic toxicity. As demonstrated by the examples, encapsulating STX in a controlled release system, such as liposomes, preferably also including a corticosteroid, and administering in suitable dosing regimen to achieve a prolonged nerve block without systemic toxicity, delays the onset of hyperalgesia.

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract: Porous biocompatible composite biomaterial, useable as a drug delivery system or as spacer or as bone substitute, such as for example for filling bone lacunae or for substituting damaged parts of bone tissue, or for fixing prosthesis of various types, or for thickening bones weakened by illness such as osteoporosis or the like, including a component adapted to form a porous structural matrix and a soluble component, wherein the soluble component is in form of powder and granules or other similar agglomerates so as to have mechanical support characteristics and osteoinductive and osteoconductive characteristics in the entire volume occupied by the biomaterial, and a method for obtaining the biomaterial.

Abstract: A biocidal glass composition for use in roofing applications can include glass doped with at least one biocidal agent that includes about 0.01 wt. % to about 50 wt. % of a total weight % of the biocidal glass composition. The biocidal glass composition can be included in a coating on a base particle of a roofing granule. Further included is a process of forming the roofing granule.

Abstract: This invention relates to a mouthwash comprising an aqueous solution of an effective amount of a basic amino acid, in free or salt form together with an effective amount of a preservative selected from methylisothiazolinone (MIT), benzyl alcohol, phenoxyethanol, and combinations thereof; as well as to methods of using and of making such compositions.

Abstract: The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L3 is a single bond, etc, R3 is alkyl, etc, L1 and L2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.

Abstract: The present invention relates to an oral care composition and a method of disinfecting the oral cavity. So far synthetic material (e.g. Triclosan) has been used which is believed by many consumers to be harsh on them. Consumers, more and more prefer using products that contain natural materials. Further, in many countries, culturally or otherwise, people are reluctant to using alcohol in their mouthwashes. The present inventors have been working on solving these problems and have come up with an oral care composition which includes natural materials that are found to interact synergistically with certain metal salts in killing S. mutans, a bacterium responsible for tooth decay.

Abstract: An odor eliminating solution comprises the active deodorizing and antimicrobial agents of silver nanoparticles dispersed in colloidal suspension in a solution containing excess sodium tetraborate decahydrate, commonly referred to as borax. The silver nanoparticles provide deodorizing and antimicrobial properties through the colloidal dispersion which provides a high surface area to volume ratio for the suspension. The sodium tetraborate decahydrate provides deodorizing and antimicrobial properties through its co-complexing ability with various substances. The combination of both provides the present invention with long term stability and deodorizing and antimicrobial activity. Furthermore, the present invention include the method for formulating the odor eliminating solution through the combination of a silver nanoparticle source solution and an aqueous sodium tetraborate solution which results in a chemical reaction that synthesizes the silver nanoparticles from the silver cations.

Abstract: Personal care compositions comprising three liquid layers, particular useful for treating hair. The compositions are visually three separate layers. One layer comprises an oil phase, one layer comprises a polyol phase, and one layer comprises a silicone phase. The compositions can be mixed homogenously upon shaking, and remain homogenous for a sufficient period of time to allow the consumer to use the product, before it separates into three distinct layers again. The compositions do not have substantial amounts of surfactants or emulsifiers, and no more than 1% of salts or mineral oil.

Abstract: The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solution, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, disinfecting or cleansing surfaces, or treating and/or preserving food products and cut flowers, among other uses.

Abstract: The present invention relates to an improved antimicrobial composition comprising a hydrogen peroxide source and one or more antimicrobial agents. Ideally, the invention relates to an antimicrobial composition comprising (i) hydrogen peroxide source and (ii) an antimicrobial agent and its associated use in therapy, particularly in the treatment of antimicrobial infections.

Abstract: A method for producing an antimicrobial cellulose fiber. The method includes reacting a reactive compound with an antimicrobial agent to prepare a reactive antimicrobial compound, chemically fixing the reactive antimicrobial compound to a cellulose fiber through chemical bonding between the reactive compound and the cellulose fiber, and stabilizing the cellulose fiber structure. Further disclosed is an antimicrobial cellulose fiber produced by the method. The antimicrobial cellulose fiber is a human friendly material that has excellent antimicrobial activity and deodorizing performance. The antimicrobial cellulose fiber can be manufactured in the form of raw cotton, sliver, roving yarn, spun yarn, woven fabric, knitted fabric, non-woven fabric, etc. The antimicrobial cellulose fiber may be blended with other fibers, such as natural fibers and synthetic fibers.

Abstract: Preparations for oral consumption are proposed, comprising (a) lactic acid 1-menthyl ester of the general formula (I) its stereoisomers or mixtures thereof, (b) at least one substance having a bitter, astringent and/or metallic taste impression, and optionally (c) further flavorings.

Abstract: Individuals having diabetes are more prone to fractures, periodontitis, and other bone related issues as compared to healthy individuals. Furthermore, bone healing in diabetic patients is prolonged. The invention provides a method for decreasing bone resorption or increasing bone formation or promoting bone healing in diabetic patients. In particular, a biodegradeable polymer, such as a polyanhydride salicylate is administered at or near a bone defect site, and upon hydrolysis of the polymer will releases biologically active salicylic acid.

Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

Abstract: The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solutions, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, and treating skin irritations, among other uses.

Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibers manufactured from these glass compositions, medical devices containing fibers of the invention, the use of these compositions for the manufacture of glass fiber and the use of the fibers for the manufacture of medical devices are also disclosed.